GeneDx Holdings CorpWGS
Price$70.96Intrinsic value$70.521% below price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $454.4M+48.8% YoYTTM through 30 Jun 2026
Net Income -$106.4MTTM through 30 Jun 2026
Free Cash Flow -$75.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin66.7%
EBITDA Margin-17.9%
Operating Margin-56.2%
Net Margin-23.4%

Returns

-30.6%ROE
-15.4%ROA

Balance Sheet Health

Debt / Equity0.38x
Current Ratio3.09x
Net Debt-$74Mnet cash position
Cash & Equivalents$60.3M

Quality Metrics

Altman Z-Score3.36
Piotroski F-Score4 / 9
FCF Margin-16.7%
Rule of 40-10.7
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $427.5M
Diluted EPS-$3.62TTM
'19'20'21'22'23'24'25
FY2025: $-0.73

Dividend

No dividend

Capital Allocation

R&D Spend$83.8M
Capex Intensity6.0%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.